SIRT3 and myocardial infarction: Lastly, through observation of whether individual or synergistic application, hSIRT3 and hTIMP3 gene therapy could effectively limit the size of the scar area after MI/R injury, as expected, synergistic therapy showed better myocardial protection than monotherapy (Fig. 8c).